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Transgenic pigs are currently the most favored potential source of organs for xenotransplantation. Like all mammalian
species they all harbor endogenous retroviruses in their genome. These porcine endogenous retroviruses (PERVs) are
produced from several primary cells and cell lines and are able to infect human cells. Here we demonstrate that different
pig strains and different animals of one strain differ in their ability to produce PERVs from normal blood cells. We report that
purified PERV particles show a protein pattern typical for type C retroviruses and are antigenically related to mammalian
leukemia viruses. Like most retroviruses, purified PERVs and peptides derived from the highly conserved immunosuppres-
sive domain of their transmembrane envelope protein inhibit human immune cell functions. This indicates that high titer
replication of PERVs in the transplant recipient could therefore lead to an immunodeficiency disease. © 2000 Academic PressINTRODUCTION
The severe shortage of human organs available for
allotransplantation is a driving force behind xenotrans-
plantation research. Clinical attempts have been made
using primate xenografts (Starzl et al., 1993), which
ould cause the fewest immunological problems. But for
thical, practical, microbiological, and financial reasons
ost attention is being focused on pigs as potential
onors of organs and tissues (Cooper et al., 1997;
iekrasz et al., 1992). First transplantations of pig cells
nd extracorporeal bridging with pig kidneys and livers
ave demonstrated the severity of the hyperacute rejec-
ion (HAR) by the human complement system induced by
reformed xenoreactive antibodies binding to galactosyl-
a-1-3-galactosyl-sugar epitopes (Stevens and Platt,
1992). Recent developments in the immunosuppressive
therapy and the use of organs from transgenic pigs
expressing human complement decay accelerating fac-
tor (DAF, CD55) and other human complement regulatory
proteins (CD59, CD46) supported the idea that the HAR
can be overcome (Cooper et al., 1997). However, trans-
lant rejection by cellular and humoral immune re-
ponses will still go on and require strong immunosup-
ression by drugs or antibodies.
In addition to prevention of transplant rejection, phys-
ological compatibility of the organ and microbiological
afety must be guaranteed before xenotransplantation
ecomes reality in the clinic (Bach et al., 1998; Fishman,
1997). Most of the xenozoonoses can be prevented by1 To whom reprint requests should be addressed. Fax: *49-6103-77-
23. E-mail: denjo@pei.de.
87specific pathogen-free breeding conditions (Swindle,
1998), as well as by screening for and vaccination
against infections that are known. This may be more
easily achieved with pigs in comparison with primates
(Allan et al., 1998).
In both cases, primates and pigs, one type of pathogen
cannot be eliminated at present, the endogenous retro-
viruses. In contrast to exogenous retroviruses, these
viruses have entered the germline of a species during
evolution and are resident as proviruses in the DNA of
the host (Lo¨wer et al., 1996). Porcine endogenous retro-
viruses (PERVs) exist as multiple copies in pigs and are
produced by pig cell lines (Breese, 1970; Lieber et al.,
1975), by pig tumors (Frazier, 1985), after cultivation of pig
aorta endothelial cells (Martin et al., 1998), and after
mitogenic stimulation of pig peripheral blood mononu-
clear cells (PBMC) (Wilson et al., 1998). The porcine
kidney cell line PK-15 (Armstrong et al., 1971; Tissier et
al., 1997; Todaro et al., 1974) and primary aorta endothe-
lial cells (Martin et al., 1998) produce at least two sub-
types, PERV-A and PERV-B, which are able to infect
human cells (Patience et al., 1997; Takeuchi et al., 1998).
Another subtype, PERV-C, is released from PBMC after
mitogenic stimulation. All three subtypes share profound
sequence homologies with substantial differences in the
receptor binding region of the viral surface envelope
gene. PERVs are related in nucleotide and amino acid
sequence (Akiyoshi et al., 1998; Tissier et al., 1997) and
morphology (Bouillant et al., 1975) to type C retroviruses
of mice, cats, and gibbons which induce in the infected
host leukemias and immunodeficiencies (Fan, 1994;
Hardy, 1993). The transmission of PERV from the trans-
plant to the recipient in xenotransplantation may there-
0042-6822/00 $35.00
Copyright © 2000 by Academic Press
All rights of reproduction in any form reserved.
s
O
l
h
1
(
C
a
t
r
s
p
1
n
e
s
H
p
e
v
f
m
g
s
m
t
r
p
P
d
t
t
n
S
c
O
d
i
f
a
(
r
i
r
d
T
P
u
s
P
B
o
h
g
88 TACKE, KURTH, AND DENNERfore lead to tumors and leukemias, mainly by insertional
mutagenesis, and/or immunodeficiencies as it is known
for these related retroviruses.
It had previously been demonstrated that many retro-
viruses are immunosuppressive and that retroviruses
which induce immunodeficiencies in vivo also inhibit
everal immune reactions in vitro (Denner, 1987, 1998b).
ne example is the inhibition of the mitogen-stimulated
ymphocyte proliferation. This has been shown for intact
uman immunodeficiency virus 1 (HIV-1) (Denner et al.,
996) as well as for inactivated noninfectious HIV-1
Pahwa et al., 1985), and also for many type D and type
retroviruses (Denner et al., 1980, 1985; Hebebrand et
l., 1977). This immunosuppressive activity was assigned
o the transmembrane envelope protein (TM) of these
etroviruses. Purified viral TM protein inhibited mitogen-
timulated lymphocyte proliferation in vitro and macro-
hage functions in vivo (Denner, 1998b; Denner et al.,
986; Mathes et al., 1979). In another example of immu-
osuppression, expression of TM protein on tumor cells
nabled these cells to grow in animals which reject the
ame cells not expressing this protein (Mangeney and
eidmann, 1998). Similar results were obtained using
eptides derived from a region of the transmembrane
nvelope which is highly conserved among most retro-
iruses (Haraguchi et al., 1997; Ruegg et al., 1989). There-
ore it has been proposed that this domain of the trans-
embrane protein may contribute to the immunopatho-
enicity of retroviruses (Denner, 1998b).
Here we show that PERV particles are released in a
train-dependent manner from normal pig PBMC after
itogen stimulation. We characterize PERV and show
hat it is antigenically related to other mammalian type C
etroviruses. Specific antisera against PERV proteins and
eptides have been used to develop diagnostic assays.
urified and inactivated PERVs inhibit the mitogen-in-
uced proliferation of human PBMC. In addition, pep-
ides corresponding to the immunosuppressive region of
he TM protein of all three PERV variants also act immu-
osuppressively.
RESULTS
train-dependent differences in PERV production
When we stimulated PBMC from outbred Yucatan mi-
ro pigs using phytohemagglutinin (PHA) or PHA and
-tetradecanoylphorbol-13-acetate (TPA), transient pro-
uction of virus particles was observed (Fig. 1), confirm-
ng previous results (Wilson et al., 1998). We show for the
irst time differences in virus production in different pigs
nd pig strains. Three out of nine Yucatan micro pigs
Charles River, France) and two out of two German land-
ace pigs did not produce virus when stimulated in an
dentical way. In the nonproducing animals even a wider
ange of stimulation conditions did not lead to release of
etectable amounts of reverse transcriptase activity.herefore, we observed strain-dependent differences in
ERV production as well as differences between individ-
als of the same strain. However, until now we did not
ucceed in infecting human kidney cells or PBMC with
ERV released from stimulated pig PBMC.
iochemical and immunological characterization
f PERV
Like all retroviruses, PERVs produced by PK-15 and
uman 293 cells band after centrifugation in sucrose
radients at a density of 1.14–1.16 g/cm3 (Fig. 2a). The
broader peak of PERV produced by PK-15 cells indicates
that in addition to viruses being able to replicate in
human 293 cells, particles were produced with other
physicochemical properties, which may be defective.
Polyacrylamide gel electrophoresis (PAGE) and Western
blot analyses show that PERVs are related to other mam-
malian type C retroviruses. Virus particles are composed
of a major Gag (group-specific antigen) core protein with
an apparent molecular weight (MW) of 27 kDa, Gag
precursor proteins (60 and 41 kDa) (Figs. 2b and 2c), and
minor Gag proteins with apparent MWs of 9 and 7 kDa
(data not shown). In contrast to PERVs, the major Gag
protein of the murine leukemia virus (MuLV), analyzed as
a control, has a MW of 30 kDa. The Gag protein of PERV
is recognized by a polyclonal antiserum against p27Gag
of feline leukemia virus (FeLV) (Fig. 2c), as well as by
antisera against the Gag proteins of baboon endoge-
nous retrovirus (BaEV) and MuLV (data not shown). As
expected, antisera against the p24Gag protein of HIV-1
do not react (data not shown). We obtained a rabbit
antiserum against purified p27Gag derived from PERV
FIG. 1. Release of PERV particles from pig PBMCs after mitogenic
stimulation. Purified PBMCs from Yucatan micro pigs and German
landrace pigs were cultured without or with 50 mg/ml PHA or 50 mg/
ml PHA and 100 ng/ml TPA. RT activity was tested in the cell-free
supernatant.grown on PK-15 cells. This serum reacts not only with the
PERV antigen but also with p30Gag from MuLV (Fig. 2d).
ERV an
89PORCINE ENDOGENOUS RETROVIRUSES INHIBIT IMMUNE CELLSPAGE analysis of PERV shows three different bands in
the range of the 70-kDa surface envelope protein (Fig.
2b), which must be analyzed further. Western blot anal-
ysis using an antiserum against gp71Env from FLV iden-
tifies only two bands, gp70 and gp85 (data not shown).
An antiserum produced against a peptide derived from
the TM protein p15E of PERV-B recognizes the 85-kDa
Env precursor and the cleaved transmembrane envelope
proteins p15E and p12E of PERV as well as of MuLV (Fig.
2e). The p12E protein probably represents p15E after cleav-
age of the C-terminal R-peptide (Ragheb and Anderson,
1994). Interestingly, additional bands are detected which
FIG. 2. Characterization of PERV. (a) Sucrose density centrifugation
human 293 cells (closed circles); (b) SDS-PAGE of gradient purified PER
with MuLV produced by FEM cells (M, molecular weight standard; Pr-
the same virus preparation shown in (b) and a goat antiserum agains
rabbit antiserum against p27 of PERV; (e) Western blot analysis using P
from p15E of PERV-B.possibly represent multimeric forms of p15E (Fig. 2d). Such
oligomerization has also been described for gp41 ofHIV-1 (Pinter et al., 1989). As expected, antibodies
against gp41 of HIV-1, and also several monoclonal
antibodies against p15E of FeLV, do not recognize p15E
of PERV. Our data therefore show that PERVs are type C
retroviruses and related to FeLV, MuLV, and BaEV. Rep-
lication of PERVs on human 293 cells led to an adapta-
tion in the sense of higher virus production (measured as
RT activity per volume, data not shown) and more mature
particles containing less Gag precursor protein (Fig. 2).
Immunosuppression by PERV
entrated PERV particles produced by PK-15 (open circles) or infected
les produced by PK-15 or by infected human 293 cells and comparison
d Pr-Env, precursors of Gag and Env); (c) Western blot analysis using
g of FeLV; (d) Western blot analysis using a MuLV preparation and a
d MuLV preparations and a rabbit antiserum against a peptide derivedof conc
V partic
Gag an
t p27GaMost, if not all, retroviruses are immunosuppressive
and the severity of immunosuppression seems to corre-
fenous
90 TACKE, KURTH, AND DENNERlate with viral load. Immunosuppressive properties have
been shown also for inactivated retroviruses, purified TM
proteins, and synthetic peptides corresponding to a
highly conserved domain in the TM protein (Denner,
1998b). To see whether PERV also acts immunosuppres-
sively we tested the influence of PERV particles purified
as described above on human PBMC stimulated by
ConA. A dose-dependent inhibition of cell proliferation
was observed (Figs. 3a and 3b). This inhibition of human
immune cells by PERV was comparable in magnitude to
that induced by MuLV in a control experiment (Fig. 3c), or
by a SRV-related type D retrovirus and by BaEV (Fig. 3d).
This inhibition was due neither to cytotoxicity of the
preparations as tested by trypan-blue exclusion assay
nor to infection, as ether-disrupted retroviruses show the
same amount of inhibition.
As previously shown by us and others, synthetic pep-
tides corresponding to a domain of the transmembrane
envelope protein highly conserved in most retroviruses
act immunosuppressively (Cianciolo et al., 1985; Denner
et al., 1994, Denner et al., 1996). The amino acid se-
quence of the imunosuppressive domains of PERV-A and
PERV-C is identical to that of MuLV, FeLV, and gibbon ape
FIG. 3. Suppression of ConA-induced proliferation of human PBMCs b
added intact (open symbols) or after disruption (closed symbols) using
rom healthy donors. [3H]Thymidine incorporation was measured after
al., 1994). (a) PERV produced by human 293 cells; (b) PERV produced
human fibroblast derived type D virus PMFV (Denner et al., 1985) p
detergent-disrupted by Triton X-100 (closed circles) and baboon endog
sarcoma cells (closed squares).leukemia virus (GaLV), whereas the sequence of PERV-B
is characterized by a conservative amino acid exchange(Fig. 4). Using these synthetic peptides of PERV-A,
PERV-B, and PERV-C conjugated to bovine serum albu-
min as carrier protein, we also show inhibition of mito-
gen-induced proliferation of human PBMC (Fig. 5) to the
same extent as the corresponding HIV-1 peptide conju-
gate used as control. The peptides are interspecies-
reactive as they also inhibit the proliferation of the IL-2-
dependent murine T cell line CTL-6 (data not shown).
and MuLV, produced and purified as described in Fig. 2. Viruses were
a, b, c) or Triton X-100 (d) to human ConA-stimulated (10 mg/ml) PBMC
and percentage of stimulation was estimated as described (Denner et
15 cells; (c) MuLV produced by FEM cells; (d) SRV-related permanent
d by human ovarial carcinoma cells added intact (open circles) or
retrovirus BaEV (Denner et al., 1980) produced by human rhabdomyo-
FIG. 4. Sequence comparison of the immunosuppressive domain of
PERV and other retroviruses. Identical amino acids are framed and
conservative exchanges (R 5 K; Y 5 F; I 5 L) are hatched. The number
in front of the sequence indicates the position of the first amino acid in
the Env polyprotein. GenBank Accession Numbers: PERV-A, Y12238;
PERV-B, Y12239; PERV-C, AF038600; Tsukuba-1, AF038599; FeLV,y PERV
ether (
4 days
by PK-
roduceM18247; MuLV, J02255; GALV, M26927; BaEV, 218569; HTLV-I, J02029;
HIV-1, K03455.
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In this report we were able to show that PERVs can be
roduced by PBMC of several Yucatan micro pig animals
ut not from the few German Landrace animals tested.
hether these differences in virus production may be
xplained by differences in the regulation of virus protein
xpression or by a different number of integrated provi-
uses as suggested by published Southern blot analyses
sing a PERV-C probe (Akiyoshi et al., 1998) remains to
e elucidated. Such a diversity has not been seen with
he human endogenous retrovirus HERV-K in the human
opulation (Lo¨wer et al., 1996). In analogy to the stimu-
lation of pig PBMC by TPA/PHA in vitro, stimulation by
the human antigen environment of pig PBMC transferred
together with the transplanted organs may lead to virus
production in vivo. It is already known that graft-versus-
host/host-versus-graft reactions, and their in vitro equiv-
alent, the mixed lymphocyte reaction, are even more
effective in activation of murine and human endogenous
retroviruses than treatment with mitogens (Denner, 1998a;
Hirsch et al., 1972). We will now test whether pig PBMC
from animals not releasing PERVs after mitogen stimulation
will do so during mixed lymphocyte reactions with human
PBMC. Our data suggest that a low virus production strain
of pigs could be selected for xenotransplantation.
The biochemical and immunological characterization
shows that PERVs are type C retroviruses related to FeLV,
MuLV, and BaEV, which are in part pathogenic. The now
available PERV proteins and peptides, as well as their
corresponding antibodies, are the necessary prerequisite
for quick and specific assays useful for detecting virus and
antibodies in experimental and clinical settings.
FIG. 5. Suppression of ConA-induced proliferation of human PBMCs
by synthetic peptides corresponding to the immunosuppressive do-
mains of PERV-A (closed squares; LQNRRGLDLLFLKEGGLC), PERV-B
(open squares; LQNRRGLDLLFLREGGLC), HIV-1 (closed circles;
KQLQARILAVGRYLKDQQL). Peptides were conjugated to BSA; a BSA
mock preparation (open circles) was used as control. Lymphocyte
stimulation was measured as described in Fig. 3. Unconjugated pep-
tides did not suppress lymphocyte proliferation and conjugates were
not toxic as demonstrated using dye exclusion assays (not shown).The second part of this report clearly shows that live
and disrupted PERV particles as well as peptides corre-sponding to the immunosuppressive domains of the TM
protein of PERV inhibit mitogen-stimulating human lym-
phocyte proliferation. This has been shown for many
other retroviruses, including those which are highly
pathogenic. In addition, the interspecies reactivity has
also been shown for HIV, that inhibits human (Cianciolo
et al., 1985; Pahwa et al., 1985; Denner et al., 1994) and
murine (Denner et al., 1996) immune cell proliferation. It
can be expected that PERVs will therefore also modulate
cytokine production and influence the intracellular regu-
lation of immune competent cells which has been shown
for other type C retroviruses and HIV-1 (Denner, 1998b;
Gottlieb et al., 1990; Haraguchi et al., 1995). We proposed
that the transmembrane protein plays an important role
in retrovirus-induced pathogenesis. The finding that viral
load correlates with disease progression (Pantaleo et al.,
1993) supports our hypothesis.
Inhibitory effects by disrupted PERVs and PERV-de-
rived peptides demonstrate the immunosuppressive po-
tential of PERVs and suggest that virus replication in
xenotransplant recipients might induce immunodeficien-
cies. Human cell lines can be infected in vitro by and
produce PERV (Patience et al., 1997; Takeuchi et al.,
1998; Tissier et al., 1997). Although our first attempts to
infect human PBMC with pig PBMC-derived PERVs
failed, Wilson et al. (1998) showed infection of human cell
lines by cocultivation with stimulated pig PBMC. How-
ever, risk evaluation must consider how successfully
PERV replicates in the organism of the transplant recip-
ient. Investigations of patients who received pig islet
cells (Heneine et al., 1998) or were connected extracor-
poreally to pig kidneys (Patience et al., 1998) showed that
these patients were not infected. Nevertheless, bridging
times were short and the number of xenotransplanted
islet cells was quite low. In a larger study Paradis et al.
(1999) investigated 160 patients who received transplanta-
tions of different pig tissues as well as ex vivo perfusion of
pig organs, but did not find any signs for PERV infection.
Furthermore several points which may favor viral rep-
lication must be considered in the case of in vivo trans-
plantations of solid organs from transgenic pigs. First,
larger amounts of cells are transferred; second, stronger
chemical immunosuppression must be applied in order
to prevent transplant rejection; third, incorporation of
human complement regulator proteins into the viral en-
velope during budding from transgenic cells would pro-
tect the virus from the human complement system; and
fourth, larger and renewing reservoirs of susceptible
target cells for PERVs may be available in vivo in com-
parison to the tissue culture in vitro.
Although PERVs are, like most retroviruses, potentially
immunosuppressive, the complex interaction of the many
different factors discussed above, such as the number of
susceptible target cells, the immune system, the com-
plement system, the use of transgenic pigs, and the
ability of the virus to replicate in and adapt to human
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92 TACKE, KURTH, AND DENNERcells will determine the final outcome in vivo. If there is
no replication in vivo as it is understood to date, there
will be no risk. However, if replication takes place at a
high level, the risk of tumor development and induction of
immunodeficiency may be substantial.
Retroviruses may be inhibited by a combined chemo-
therapy using inhibitors of reverse transcriptase and
protease (Carpenter et al., 1997), by antiviral peptides
Chan and Kim, 1998), as well as by vaccines (Montelaro
nd Bolognesi, 1995). In contrast to the situation with
IV-1 successful vaccines against type C retroviruses
ave been developed (Montelaro and Bolognesi, 1995).
e are now developing PERV-specific antiviral peptides
nd strategies for a vaccine which may be used in the
ase PERV is replicating in humans.
MATERIALS AND METHODS
irus purification
PERVs were produced by pig kidney PK-15 cells (ATCC,
SA) or infected human 293 kidney cells (kindly provided by
r. R. Weiss, Institute of Cancer Research, Chester Beatty
aboratories, London). Cell-free culture supernatant was
elleted, resuspended pellets were purified by standard
ucrose gradient centrifugation (20–50%), and fractions
ere collected. The murine Friend leukemia virus (FLV)
rown on Friend-Evelyne-Monolayer (FEM) cells was puri-
ied employing the same method. For monitoring virus pro-
uction and fraction analysis a commercial reverse tran-
criptase ELISA assay (Calvidi-Tech, Uppsala, Sweden)
as used. Protein content was measured with the BCA
ssay (Pierce, Rockford, IL).
DS-PAGE and Western blot assays
SDS-PAGE was performed in 12% gels which were
tained with Coomassie blue. For immunodetection after
lectrophoresis proteins were transferred from gels to
VDF membranes (Millipore, Bedford, MA). Viral proteins
ere detected using different antisera or monoclonal
ntibodies. After incubation with peroxidase-conjugated
rotein G (Biorad, Hercules, CA), blots were stained
sing hydrogen peroxide and diaminobenzidine with
etal enhancer (Pierce).
eptide synthesis, carrier protein conjugation
Peptides were synthesized using the Fmoc chemistry,
urified by HPLC, characterized by mass spectroscopy,
nd conjugated to the carrier protein bovine serum al-
umin (BSA) using the carbodiimide EDC method as
reviously described (Denner et al., 1994).
ntisera
Proteins of gradient-purified PERV produced by PK-15
ells were separated by SDS-PAGE and the protein band
27Gag was cut out after negative staining with KCl. A
Cpeptide corresponding to the immunosuppressive do-
main of PERV-B (LQNRRGLDLLFLKEGGLC) was conju-
gated to keyhole limpet hemocyanin using glutaralde-
hyde. For primary and booster immunization, protein
bands and peptide conjugates were mixed with adjuvant.
Proliferation assays
For activation of PERVs, gradient-purified pig PBMC
were treated with PHA (50 mg/ml; Murex, Dartford, UK) or
HA (50 mg/ml) and TPA (100 ng/ml; Sigma, St. Louis,
O). Virus release was measured as reverse transcrip-
ase activity. To study the effect of PERV on human
mmune cells, gradient-purified human PBMC were stim-
lated with concanavalin A (ConA; 10 mg/ml; Sigma) and
urified intact or ether-disrupted virus, peptides, peptide
onjugates, or mock conjugates were added simulta-
eously with the mitogen. [3H]Thymidine incorporation was
easured on Day 4 as described (Denner et al., 1994).
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